OncoSec Medical, Inc. (ONCS) Announces Patient Enrollment and Screening Sites for Phase II Melanoma Clinical Trial
OncoSec Medical, a biopharm company developing its advanced-stage OMS ElectroOncology therapies for the treatment of solid tumor cancers and metastatic disease, today announced it has initiated the John Wayne Cancer Institute in Santa Monica, Calif., and Lakeland Comprehensive Cancer Center in Lakeland, Fla., as patient enrollment and screening sites for its phase II metastatic melanoma clinical trial (OMS-1100) for the company’s OMS Electro Immunotherapy treatment. OncoSec Medical plans to enroll 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma. Patients will receive one treatment cycle with three treatments applied to up to four lesions on days one,…